尼达尼布治疗特发性肺纤维化患者的长期安全性与耐受性:INPULSIS-ON开放标签扩展研究结果
INPULSIS-ON是一项开放标签扩展研究,纳入完成52周INPULSIS试验的807例特发性肺纤维化患者中的734例(91%),其中430例(59%)继续尼达尼布治疗,304例(41%)由安慰剂转为尼达尼布。尼达尼布在INPULSIS和INPULSIS-ON中均治疗的患者中位暴露时间为44.7个月(范围11.9-68.3)。INPULSIS-ON的安全性特征与INPULSIS一致,腹泻是最常见不良事件(继续治疗组60.1事件/100患者暴露年,新起始组71.2事件/100患者暴露年)。结论提示尼达尼布长期使用安全性可管理,无新安全信号。
要点
- 腹泻是尼达尼布最常见不良事件:继续治疗组60.1事件/100患者暴露年,新起始组71.2事件/100患者暴露年。
- 因腹泻永久停药:继续尼达尼布组20/430例(5%),新起始尼达尼布组31/304例(10%)。
- 因特发性肺纤维化进展永久停药最常见:继续治疗组51/430例(12%),新起始组43/304例(14%)。
- 出血事件率:继续治疗组8.4事件/100患者暴露年,新起始组6.7事件/100患者暴露年。
- 主要不良心血管事件率:继续治疗组3.6事件/100患者暴露年,新起始组2.4事件/100患者暴露年。
适用人群与场景
- 完成INPULSIS试验52周治疗期及4周后随访访视的特发性肺纤维化患者。
- INPULSIS与INPULSIS-ON之间停药期可为4-12周。
处置流程与药物剂量
- INPULSIS试验结束时接受尼达尼布150 mg每日两次或安慰剂的患者,在INPULSIS-ON中接受尼达尼布150 mg每日两次。
- INPULSIS试验结束时接受尼达尼布100 mg每日两次或安慰剂的患者,在INPULSIS-ON中可接受尼达尼布100 mg每日两次或150 mg每日两次。
- 肺功能检查在基线、第2、4、6、12、24、36、48周进行,之后每16周进行。
研究设计与关键结果
- 开放标签扩展研究;807例完成INPULSIS试验的患者中734例(91%)在INPULSIS-ON中接受治疗;430例(59%)继续尼达尼布,304例(41%)由安慰剂转为尼达尼布。
- 尼达尼布在INPULSIS和INPULSIS-ON中均治疗的患者中位暴露时间为44.7个月(范围11.9-68.3)。
- INPULSIS-ON中尼达尼布安全性特征与INPULSIS一致;腹泻是最常见不良事件(继续治疗组60.1事件/100患者暴露年,新起始组71.2事件/100患者暴露年)。
- 因腹泻永久停药:继续尼达尼布组20/430例(5%),新起始尼达尼布组31/304例(10%)。
- 因特发性肺纤维化进展永久停药最常见:继续尼达尼布组51/430例(12%),新起始尼达尼布组43/304例(14%)。
- 出血事件率:继续尼达尼布组8.4事件/100患者暴露年,新起始尼达尼布组6.7事件/100患者暴露年。
- 主要不良心血管事件率:继续尼达尼布组3.6事件/100患者暴露年,新起始尼达尼布组2.4事件/100患者暴露年。
- 心肌梗死(宽口径,即所有可能病例)事件率:继续尼达尼布组1.3事件/100患者暴露年,新起始尼达尼布组0.7事件/100患者暴露年。
证据类型、等级与局限
- 研究类型:开放标签扩展研究(INPULSIS-ON)。
- 作者结论:这些发现提示尼达尼布长期使用具有可管理的安全性和耐受性特征,无新安全信号;特发性肺纤维化患者可长期使用尼达尼布以延缓疾病进展。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为尼达尼布长期使用安全性可管理,无新安全信号,特发性肺纤维化患者可长期使用以延缓疾病进展。
- 腹泻是长期治疗中最常见不良事件,继续治疗组60.1事件/100患者暴露年,新起始组71.2事件/100患者暴露年;因腹泻永久停药继续治疗组5%、新起始组10%。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The efficacy and safety of nintedanib, an intracellular tyrosine kinase inhibitor, in patients with idiopathic pulmonary fibrosis were assessed in two phase 3, placebo-controlled INPULSIS trials. Patients who completed the 52-week treatment period in an INPULSIS trial could receive open-label nintedanib in the extension trial, INPULSIS-ON. We aimed to assess the long-term efficacy and safety of nintedanib in INPULSIS-ON.
METHODS: Patients who completed the 52-week treatment period of INPULSIS, and the follow-up visit 4 weeks later, were eligible for INPULSIS-ON. The off-treatment period between INPULSIS and INPULSIS-ON could be 4-12 weeks. Patients receiving nintedanib 150 mg twice daily or placebo at the end of an INPULSIS trial received nintedanib 150 mg twice daily in INPULSIS-ON. Patients receiving nintedanib 100 mg twice daily or placebo at the end of an INPULSIS trial could receive nintedanib 100 mg twice daily or 150 mg twice daily in INPULSIS-ON. Spirometric tests were done at baseline, at weeks 2, 4, 6, 12, 24, 36, 48, and then every 16 weeks. The primary outcome of INPULSIS-ON was to characterise the long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis, and this was analysed in patients who received at least one dose of nintedanib in INPULSIS-ON. This study is registered with ClinicalTrials.gov, number NCT01619085, and with EudraCT, number 2011-002766-21.
FINDINGS: The first patient was enrolled into INPULSIS-ON in July 2, 2012. Of 807 patients who completed the INPULSIS trials, 734 (91%) were treated in INPULSIS-ON. 430 (59%) patients had received nintedanib in INPULSIS and continued nintedanib in INPULSIS-ON, and 304 (41%) had received placebo in INPULSIS and initiated nintedanib in INPULSIS-ON. Median exposure time for patients treated with nintedanib in both the INPULSIS and INPULSIS-ON trials was 44·7 months (range 11·9-68·3). The safety profile of nintedanib in INPULSIS-ON was consistent with that observed in INPULSIS. Diarrhoea was the most frequent adverse event in INPULSIS-ON (60·1 events per 100 patient exposure-years in patients who continued nintedanib, 71·2 events per 100 patient exposure-years in patients who initiated nintedanib). 20 (5%) of 430 patients who continued nintedanib and 31 (10%) of 304 patients who initiated nintedanib permanently discontinued nintedanib because of diarrhoea. The adverse event that most frequently led to permanent discontinuation of nintedanib was progression of idiopathic pulmonary fibrosis (51 [12%] patients continuing nintedanib and 43 [14%] patients initiating nintedanib). The event rate of bleeding was 8·4 events per 100 patient exposure-years in patients who continued nintedanib and 6·7 events per 100 patient exposure-years in patients who initiated nintedanib. The event rate of major adverse cardiovascular events was 3·6 events per 100 patient exposure-years in patients who continued nintedanib and 2·4 events per 100 patient exposure-years in patients who initiated nintedanib. The event rate of myocardial infarction using the broad scope (ie, all possible cases) was 1·3 events per 100 patient exposure-years in patients who continued nintedanib and 0·7 events per 100 patient exposure-years in patients who initiated nintedanib.
INTERPRETATION: These findings suggest that nintedanib has a manageable safety and tolerability profile over long-term use, with no new safety signals. Patients with idiopathic pulmonary fibrosis could use nintedanib over the long-term to slow disease progression.
FUNDING: Boehringer Ingelheim.
参考来源
- Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2018. PMID: 30224318. doi:10.1016/S2213-2600(18)30339-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。